Bristol-Myers Squibb stock heads toward October 29 results

Published on 09/29/2026 at 17:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bristol-Myers Squibb stock heads toward October 29, 2026, results after quarterly EPS reached USD 2.04 versus USD 1.60 consensus. Its dividend is USD 0.63 per share.

Pharmazeutisches Forschungslabor mit NYC-Skyline, Wissenschaftler bei der Arbeit — Bristol-Myers Squibb US1078421011 zeigt Wissenschaftler in modernem New Yorker Onkologie-Labor mit Stadtpanorama, Illustration mit AI erstellt.

Bristol-Myers Squibb stock is approaching a defined earnings checkpoint after the company scheduled its third-quarter 2026 results for October 29, 2026. The latest quarterly figures cited by MarketBeat showed adjusted? EPS of USD 2.04 against USD 1.60 consensus and revenue of USD 12.97 billion against USD 11.74 billion expected.

October 29 sets the next test

Bristol Myers Squibb said on September 18, 2026, that it will report third-quarter results on October 29, 2026, followed by an investor call at 8:00 a.m. ET. The date gives investors a concrete checkpoint for assessing whether newer medicines can continue to offset pressure on mature products.

The latest reported quarter also delivered a quantified comparison: revenue increased 5.7 percent year over year, while EPS exceeded consensus by USD 0.44. MarketBeat reported that the prior-year quarterly EPS was USD 1.46, putting the latest USD 2.04 figure USD 0.58 higher.

Pipeline progress meets patent pressure

Pipeline execution remains central to the earnings narrative. In a September 8, 2026 release, Bristol Myers Squibb said its Phase 2 QUINTESSENTIAL trial met its primary endpoint in heavily pretreated multiple myeloma patients. The result supports the oncology pipeline, while the company still faces the commercial challenge of replacing revenue from established medicines as patent protection expires.

Analyst expectations remain measurable rather than uniform. MarketBeat reported a Moderate Buy consensus and an average 12-month target of USD 67.06, with recent targets ranging from USD 64.00 to USD 82.00.

Dividend adds an income checkpoint

Bristol Myers Squibb declared a quarterly dividend of USD 0.63 per share on September 16, 2026, payable November 2, 2026, to shareholders of record on October 2, 2026. For investors, the upcoming earnings date and the pipeline conversion rate are the two concrete tests alongside dividend coverage.